Arrowhead Pharmaceuticals Inc logo

Arrowhead Pharmaceuticals Inc

ARWR
Healthcare|Biotechnology|USA
$59.50
-1.62 (-2.65%)
Tangible Book
$4.09
Graham Number
$11.87

Clinical Trials (71)

TrialConditionsPhaseStatusEnrollmentDesignDrug
NCT06822790
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
Hypertriglyceridemia
P3
Recruiting869Open-labelPlozasiran Injection
NCT06366698
Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia
Iron Deficiency Anemia of Pregnancy
P3
Recruiting900RCT, Open-labelVenofer 200 MG Per 10 ML Injection, Ferrous sulfate
NCT03936361
Statins In Intracerbral Hemorrhage
Intracerebral Hemorrhage
P3
Recruiting1,456RCT, Single-blindStatins
NCT06347003
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
Severe Hypertriglyceridemia
P3
Active446RCT, Double-blindPlozasiran Injection, Placebo
NCT06347016
Study of Plozasiran in Adults With Severe Hypertriglyceridemia
Severe Hypertriglyceridemia
P3
Active311RCT, Double-blindPlozasiran Injection, Placebo
NCT06347133
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
Hypertriglyceridemia
P3
Active1,456RCT, Double-blindPlozasiran Injection, Placebo
NCT05089084
Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)
Familial Chylomicronemia
P3
Active75RCT, Double-blindPlozasiran, Placebo
NCT07037771
A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
Homozygous Familial Hypercholesterolemia
P3
Recruiting60RCT, Double-blindzodasiran Injection, Placebo
NCT06880770
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
Severe Hypertriglyceridemia
P3
Recruiting288RCT, Double-blindPlozasiran, Placebo
NCT07221344
Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease
Alzheimer Disease, Alzheimer Disease, Early Onset
P1P2
Recruiting112RCT, Double-blindARO-MAPT-SC, Placebo
NCT06700538
Study of ARO-INHBE in Adults With Obesity With and Without Diabetes Mellitus
Obesity
P1P2
Recruiting120RCT, Double-blindARO-INHBE, Placebo, Tirzepatide
NCT06131983
Study of ARO-DUX4 in Adult and Adolescent Patients With Facioscapulohumeral Muscular Dystrophy Type 1
Facio-Scapulo-Humeral Dystrophy
P1P2
Recruiting60RCT, Double-blindARO-DUX4 for Injection, Placebo
NCT07223658
Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia
Hyperlipidemia; Mixed
P1P2
Recruiting78RCT, Double-blindARO-DIMERPA, Placebo
NCT06138743
Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy
Myotonic Dystrophy 1
P1P2
Recruiting78RCT, Double-blindARO-DM1 Intravenous (IV) Infusion, Placebo Intravenous (IV) Infusion, ARO-DM1 subcutaneous (SC) injection, Placebo Subcutaneous (SC) Injection
NCT06937203
Study of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus
Obesity, Diabetes Mellitus, Type 2
P1P2
Recruiting126RCT, Double-blindARO-ALK7, Placebo
NCT05217667
Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)
Homozygous Familial Hypercholesterolemia
P2
Active18RCT, Open-labelARO-ANG 3 Injection
NCT06209177
Study of ARO-CFB in Adult Healthy Volunteers
IgA Nephropathy
P1
Active49RCT, Double-blindARO-CFB, Placebo
NCT06543290
Azithromycin Before Induction
Infections
P1
Recruiting400RCT, Double-blindAzithromycin Pill, Placebo
NCT06672445
Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2
Spinocerebellar Ataxia Type 2
P1
Recruiting36RCT, Double-blindARO-ATXN2 Injection, Placebo
NCT06827288
Adaptive Interventions for Emergency Department Patients With Opioid Use Disorder
Opioid Use Disorder
N/A
Recruiting500RCT, Open-label
NCT02299414
Chronic Hypertension and Pregnancy (CHAP) Project
Hypertension
P4
Completed2,408RCT, Open-labelAnti-hypertensive therapy
NCT01736449
Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management
Pterygium
P4
Completed31RCT, Open-labelBevacizumab
NCT03469947
California Prehospital and In Hospital Antifibrinolytic Therapy Via TXA
Hemorrhagic Shock, Trauma Injury
P3
Completed200Open-labelTranexamic Acid
NCT05902598
A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome
Familial Chylomicronemia Syndrome
P3
Completed37RCT, Double-blindPlozasiran, Placebon
NCT07056062
Oral Calcium Supplementation in Labor
Uterine Contraction, Labor Complication
P2P3
Completed89RCT, Open-labelCalcium carbonate
NCT07473843
Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia
Homozygous Familial Hypercholesterolemia
P3
Not Yet Recruiting12Open-labelZodasiran
NCT04375514
Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis
Cystic Fibrosis, Pulmonary
P1P2
Terminated43RCT, Double-blindARO-ENaC, Placebo
NCT02604212
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection
Hepatitis B
P2
Terminated32RCT, Double-blindARC-520, entecavir, antihistamine, tenofovir
NCT03365947
Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)
Hepatitis B
P1P2
Completed114RCT, Double-blindARO-HBV, JNJ-56136379
NCT05083364
Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease
C3 Glomerulopathy, IgA Nephropathy
P1P2
Completed62RCT, Double-blindARO-C3, Placebo
NCT04998201
Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia
Mixed Dyslipidemia
P2
Completed353RCT, Double-blindARO-APOC3, Placebo
NCT07241546
Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma
Asthma
P2
Not Yet Recruiting36RCT, Double-blindARO-RAGE, Placebo
NCT04832971
Study of ARO-ANG3 in Adults With Mixed Dyslipidemia
Mixed Dyslipidemia
P2
Completed204RCT, Double-blindARO-ANG3, Placebo
NCT02452528
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
Chronic Hepatitis B
P2
Terminated4RCT, Double-blindARC-520, Placebo, Entecavir, Tenofovir, diphenhydramine
NCT05537025
Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
P1P2
Completed105RCT, Double-blindARO-MMP7 Inhalation Solution, Placebo
NCT02349126
Study of ARC-520 in Patient With Chronic Hepatitis B Virus
Chronic Hepatitis B
P2
WithdrawnOpen-labelARC-520 Injection
NCT02604199
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection
Hepatitis B
P2
Terminated58RCT, Double-blindARC-520 Injection, entecavir, tenofovir, antihistamine
NCT05276570
Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease
Asthma
P1P2
Completed127RCT, Double-blindARO-RAGE, Placebo
NCT04202354
Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH
Non-alcoholic Steatohepatitis
P1P2
Completed50RCT, Double-blindARO-HSD Injection, sterile normal saline (0.9% NaCl)
NCT03946449
Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
Alpha 1-Antitrypsin Deficiency
P2
Completed16Open-labelARO-AAT
NCT05292950
Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease
Asthma, Chronic Obstructive Pulmonary Disease
P1P2
Terminated78RCT, Double-blindARO-MUC5AC, Placebo
NCT02738008
Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection
Hepatitis B
P2
Terminated12Open-labelARC-520 Injection, entecavir, tenofovir, antihistamine
NCT02577029
Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)
Hepatitis B, Hepatitis D
P2
Terminated79Open-labelARC-520, entecavir, pegylated interferon alpha 2a, tenofovir disoproxil, antihistamine
NCT02900183
Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels
Alpha-1 Antitrypsin Deficiency
P2
WithdrawnOpen-labelARC-AAT Injection
NCT05413135
Study of ARO-APOC3 in Adults With Dyslipidemia
Dyslipidemias
P2
Completed418Open-labelARO-APOC3
NCT04720534
Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia
Severe Hypertriglyceridemia
P2
Completed229RCT, Double-blindARO-APOC3, Placebo
NCT02065336
A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
Hepatitis B, Chronic
P2
Terminated58RCT, Double-blindARC-520, Placebo, entecavir, chlorpheniramine
NCT03945292
Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)
Alpha 1-Antitrypsin Deficiency
P2
Completed40RCT, Double-blindFazisiran Injection
NCT03747224
Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients
Dyslipidemias, Familial Hypercholesterolemia
P1
Completed93RCT, Double-blindARO-ANG3, sterile normal saline (0.9% NaCl)
NCT02797522
A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)
Hepatitis B
P1
Terminated47RCT, Double-blindARC-521 Injection, antihistamine, acetaminophen, entecavir, tenofovir
NCT05533294
Study of ARO-RAGE in Healthy Subjects
Asthma
P1
Completed43RCT, Double-blindARO-RAGE Injection, Placebo
NCT05757596
Study of VSA001 Injection in Chinese Healthy Adult Volunteers
Healthy Adult Volunteers
P1
Completed24RCT, Double-blindVSA001 injection, Placebo
NCT03362242
Study of ARO-AAT in Normal Adult Volunteers
Alpha 1-Antitrypsin Deficiency
P1
Completed45RCT, Double-blindARO-AAT Injection
NCT03783377
Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)
Hypertriglyceridemia, Familial Chylomicronemia
P1
Completed112RCT, Double-blindARO-APOC3, sterile normal saline (0.9% NaCl)
NCT02363946
A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)
Alpha-1 Antitrypsin Deficiency
P1
Terminated65RCT, Double-blindARC-AAT Injection, Diphenhydramine
NCT02535416
A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers
Healthy
P1
Completed40Open-labelARC-520, cetirizine, diphenhydramine
NCT04169711
Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
P1
Completed26Open-labelARO-HIF2
NCT01872065
Safety and Tolerability Study of ARC-520 in Healthy Volunteers
Healthy
P1
Completed54RCT, Double-blindARC-520, Placebo
NCT05949294
Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
P1
WithdrawnOpen-labelARO-SOD1 Injection
NCT05400382
Mindfulness to Reduce Post-cesarean Pain and Prevent Postpartum Depression
Depression, Unipolar, Pain, Postoperative
N/A
Unknown75RCT, Open-label
NCT01465516
Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir
Hepatitis C Infection
Terminated105Boceprevir
NCT06402669
Extremity Trauma At a Level 1 Trauma Center
Trauma Injury, Trauma Blunt
Completed20,000
NCT02485262
Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience
Hepatitis C
Unknown340Sofosbuvir and simeprevir
NCT05897528
Insulin Regulation and Severity of Severe Acute Respiratory Syndrome COVID-19 Infection
COVID-19, Diabetes Mellitus
Completed589
NCT06796426
Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS
Familial Chylomicronemia, High Risk Severe Hypertriglyceridemia (SHTG)
AVAILABLEPlozasiran
NCT05888363
Management and Removal of Foreign Bodies in the Emergency Department
Rectal Foreign Body, Rectal Perforation
Completed78
NCT05964088
Mortality and Morbidity Associated With New Onset Acute Kidney Injury in Critically Ill COVID-19 Infection Patients
Acute Kidney Injury
Completed267
NCT05611398
Lactate Monitoring in Traumatic Long Bone Fractures Requiring Emergent Surgical Intervention
Lactate Blood Increase, Trauma Blunt
Completed164
NCT05859958
ABO Blood Group Type Association With COVID-19 Severity
COVID-19, Blood Group Antigen Abnormality
Completed599
NCT05612867
Low Dose Vitamin C in Burns >20% Compared to Previous Studies With High Dose Vitamin C
Burns, Ascorbic Acid Deficiency
Completed54
NCT05611385
Amphetamine Induced Adult Respiratory Distress Syndrome
Burns, Acute Lung Injury
Completed49